InFoods IBS Commercial Progress Medicare-related test orders increased 120 in September 2026 compared to August, with growing physician participation and repeat ordering activityInFoods IBS update 100 of all initial vali
Biomerica Inc (BMRA) — Live Session & Technical Brief
Updated Nov 16, 2026 2:42 PM ET · Prev Close $1.36
Session Regime & Catalyst Assessment
64% Signal ConvictionControlled Session Consolidation (+0.00%) in Medical Devices
Biomerica Inc (BMRA) is trading within a tight intraday band at $1.36 (+0.00%, 0.70x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, BMRA is outperforming the S&P 500 by +1.89%. 14-day RSI stands at 28.0, keeping momentum in a oversold regime.
InFoods IBS Commercial Progress Medicare-related test orders increased 120 in September 2026 compared to August, with growing physician participation and repeat ordering activityInFoods IBS update 100 of all initial vali
Price ($1.36) trades relative to 20-day SMA ($1.62) and 50-day SMA ($1.96).
Market & Sector Relative Strength
BMRA outperforming the S&P 500 by +1.89%Recent BMRA Catalyst Headlines
Verified WireFiscal 2026 fourth quarter net sales increased approximately 17 compared to the fourth quarter of fiscal 2025Full-year net loss improved by approximately 24 to approximately 3.8 millionInFoods IBS update 100 of all initi
Financing priced at 1.60 with no warrants or discountB. Riley Principal Capital and B. Riley executives, as well as Biomerica's CEO and all members of Biomerica s Board of Directors participated in the financingProceeds
Auto-renewing Master Services Agreement engages Biomerica s integrated development and manufacturing platform, reflecting the Company s CDMO strategy as a capital-efficient, parallel revenue stream alongside its core inF
1–3 Day Expected Range & Key Level
48% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $1.39 (session resistance) for directional breakout confirmation.
Technical Regime (BMRA)
BEARISH MA TRENDRetail & Crowd Sentiment
BearishBiomerica, Inc. ($BMRA) announced a contract-development agreement with initial target fees exceeding $1.75 million. The work is expected to utilize existing facilities and staff.
About Biomerica Inc
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which …
Get Instant BMRA Catalyst Alerts
Receive an email alert when BMRA triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversBMRA Session & Catalyst FAQ
Why is BMRA stock trading near flat today?
Biomerica Inc (BMRA) is trading within a tight intraday band at $1.36 (+0.00%, 0.70x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, BMRA is outperforming the S&P 500 by +1.89%. 14-day RSI stands at 28.0, keeping momentum in a oversold regime.
Is BMRA stock a buy or sell right now?
Today's session carries a 64% catalyst conviction score on 0.70x relative volume (low participation). Our multi-factor model currently rates BMRA as HOLD. Review full valuation, quality, and timing signals on the BMRA Buy or Sell Decision Brief →
What is BMRA's intrinsic value and expected trading range?
At $1.36, BMRA's modeled 1-to-3 session range is $1.33 – $1.39, with a key inflection level at $1.39 (session resistance). Compare current price against multi-year cash flow projections in the BMRA Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for BMRA?
RSI at 28.0 indicates oversold conditions — watch for mean-reversion support. BMRA trades at $1.36 relative to its 20-day SMA ($1.62) and 50-day SMA ($1.96), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.